Aberrant expression of CD56 by circulating Sézary syndrome malignant T lymphocytes

Figure 1 Evolution of the percentage of circulating KIR3DL2⁺ (○) and CD56+ (□) CD4⁺ T lymphocytes among the total CD4⁺ T cell population, and of Sézary cell count (▲) from April to December. N1: November/sample 1; N2: November/sample 2.

Figure 2 Immunostainings of the CD4⁺ T lymphocyte population. Cells were positive for KIR3DL2, CD56, CD45RO and CCR4, but negative for the NK cell markers CD16, CD160 and NKp46 and for the activation markers NKp44 and CD69. Analyses were performed on a FC500 flow cytometer (Beckman Coulter).